Antivirals (A61P31/12)

A   Human necessities(312083)
A61P31/12                     Antivirals(672)
Forzicyaside sulfate and its derivatives, method for its production and its application // 2642784
FIELD: pharmacology.SUBSTANCE: invention relates to forzicyaside sulfate and its derivative represented by the following formula , wherein R is Na+, K+ or NH+, and a method for their preparation, as well as an antiviral drug based on them and its use.EFFECT: increased efficiency of agents.10 cl, 9 tbl, 2 dwg
ethod for prevention and treatment of dangerous neuroviral infections // 2642312
FIELD: medicine.SUBSTANCE: for treatment of dangerous neuroviral infections, mice are injected with Moliksan® in a single dose of 20.0 mg/kg of body weight immediately after infection and after 24, 48, 72 hours.EFFECT: increased effectiveness of combating diseases caused by pathogens of dangerous neuroviral infections.6 tbl

Peptides suppressing respiratory viruse infections, their application and methods for obtaining // 2639559
FIELD: pharmacology.SUBSTANCE: inventions relate to a peptide synthesized chemically or genetically engineered, compositions comprising such a peptide, DNA coding a polypeptide, vector incorporating such a DNA, a host cell for expression of the peptide, a peptide screening Kit, capable of suppressing a respiratory virus infection and a method for screening of a peptide capable of suppressing a respiratory virus infection. The presented peptide contains 5 or more essential amino acids, 2 or more of these essential amino acids are located in the N-terminal or C-terminal region, and the N-terminal region contains a sequence of no more than 10 amino acids from the peptide N-terminal amino acid and the C-terminal region contains a sequence of no more than 10 amino acids from the peptide C-terminal amino acid, while the peptide consists of a sequence of amino acids, at least 90% identical to SEQ ID NO: 10.EFFECT: possibility of application of inventions to block infections of respiratory viruses such as influenza viruses or coronaviruses in the target cells for prevention and treatment of these infections.23 cl, 10 dwg, 3 tbl, 1 ex
Ethyl (3s,4r,5s)-4-acetamido-5-amino-3-(1-ethyl propoxy) cyclohex-1-en-1-carboxylate etoxy succinate as anti-viral drug and method for its production // 2639158
FIELD: pharmacology.SUBSTANCE: invention relates to ethyl (3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-en-1-carboxylate ethoxy succinate having antiviral activity. The compound of the invention is prepared by ethyl(3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-en-1-carboxylate treatment with ethoxysuccinic acid in ethyl acetate. .EFFECT: improvement of the method.2 cl, 1 tbl, 2 ex
Indasole inhibitors of wnt signal path and their therapeutic applications // 2638932
FIELD: medicine.SUBSTANCE: invention relates to a indasole derivative that has the following formula , or its pharmaceutically acceptable salt, as well as a pharmaceutical composition containing it. The invention relates to methods for treatment of disorders characterized by the activation of Wnt-signalling pathways (e.g., cancer, abnormal cell proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), including introduction of a therapeutically effective amount of this compound or pharmaceutically acceptable salt thereof. This compound can also be used in modulation of cellular events, mediated by Wnt-signalling, as well as for treatment of genetic diseases and neurological conditions/disorders/diseases due to mutations or disregulation of the Wnt pathway and/or one or more components of Wnt-signalling.EFFECT: inhibits the Wnt signalling pathway and can be used to treat various diseases and pathologies.28 cl, 8 tbl, 8 ex

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods for application // 2638552
FIELD: pharmacology.SUBSTANCE: invention relates to pyrazol-4-yl-heterocyclylcarboxamide compounds of Formula I , including their stereoisomers, tautomers and pharmaceutically acceptable salts, wherein X is a thiazolyl, pyrazinyl, pyridinyl or pyrimidinyl group, R1 and R2 have the meanings indicated in the claims. The compounds of formula I are useful for Pim kinase inhibition and for treatment of disorders such as cancer mediated by Pim kinase. Methods for application of formula I compounds for in vitro, in situ and in vivo diagnosis, prevention or treatment of such diseases in mammalian cells or acssociated pathological conditions are disclosed.EFFECT: increased efficiency of treatment.26 cl, 4 tbl, 528 ex
ethod for immune therapy of chronic viral hepatitis c // 2637631
FIELD: medicine.SUBSTANCE: patient receives autologous dendritic cells that are generated from peripheral blood cells using differentiation inducers loaded with antigens encoding viral proteins and induced to further maturation. Interleukin-2 is prescribed as adjuvant. As a antigen, a combination of fragments of recombinant viral Core (1-120 aq) and NS3 (1192-1457 aq) proteins is used, DC maturation is induced with azoximer bromide, dendritic cells are administered as 2 courses of subcutaneous vaccination, combining DC administration with subcutaneous intermittent injections of recombinant interleukin-2 as an adjuvant non-specific therapy for patients with chronic viral hepatitis C. Granulocyte-macrophage colony-stimulating factor and interferon-alpha are used as dendritic cells differentiation inducers.EFFECT: method enables an increase of clinical effectiveness.2 cl, 2 tbl, 3 ex

ethods for glycosginophylipids obtaining and their application // 2636587
FIELD: pharmacology.SUBSTANCE: method for preparation of a compound of formula , where R1 is OH, X is C8 alkylene, R3 is OH or H, R4 is OH or H, R5 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl, provided that when R3 is H and R4 is H, then R5 is phenyl substituted with one or two groups independently selected from -F, -Cl, -Br, -OCH3, -OCH(CH3)2, -OPh, -OPh(4-F), 2-(5-F)-pyridinyl, -CF3, -NO2, -N(CH3)2 and 3-(6-F)-O-pyridinyl; or R5 is pyridinyl substituted by a group independently selected from -F- or -OPh (4-F); when R3 is H and R4 is OH, then R5 is phenyl substituted by a group independently selected from -F- or -OCH3, or R5 is phenyl substituted by two -F; when R3 is OH and R4 is OH, then R5 is phenyl substituted by one or two groups independently selected from -F or -OCH3; includes: (a) formula compound reacting with a formula compound in the presence of Lewis acid to form a formula compound, wherein PG is a hydroxyl protecting group and LG is a thiol-containing leaving group of the formula: , , or ; (b) formula (5) compound reduction to obtain a formula compound; (c) formula (3) compound combination with a formula compound, where X is C8 alkylene or C8 alkenylene to provide a formula compound and deprotection of the formula (2) compound, where PG is a hydroxyl protecting group, by hydrogen under hydrogenation catalysis conditions to obtain the formula (1) compound.EFFECT: new compounds, effective as ligands for natural killer T cells, new efficient methods for their production and new antiviral, antibacterial, antineoplastic agents based on them are proposed.23 cl, 39 ex, 1 tbl, 9 dwg

Glycosylated polypeptide and its pharmaceutical composition // 2636456
FIELD: pharmacology.SUBSTANCE: glycosylated polypeptide with a homogeneous structure of the sugar chain and having interferon-β activity is obtained synthetically.EFFECT: sugar chain structure homogeneity and presence of sialic acid on the non-reducing end of the sugar chain increases the half-life of the glycosylated form of interferon in blood and improves its pharmacokinetic properties.12 cl, 50 dwg, 2 tbl, 12 ex
Immunogen peptides and "epivakebol" vaccine against ebola fever with application of indicated peptides // 2635998
FIELD: medicine.SUBSTANCE: immunogen peptide used as a component of the vaccine against Ebola fever, characterized by the amino acid sequence PQSLTTKPGPDNSTHNTPVYKLDISE (SEQ ID NO: 1), containing the antigenic epitopes of the GP protein of the Ebola virus, which have an ability to induce the formation of virus neutralizing antibodies to protect against the development of Ebola fever, is obtained. The second immunogen peptide used as a component of the vaccine against Ebola fever is characterized by the amino acid sequence HHQDTGEESASSGKLGLITNTIAG (SEQ ID NO: 2) containing the antigenic epitopes of the GP protein of the Ebola virus. The group of inventions also relates to a vaccine comprising a peptide-immunogen mixture having the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, wherein the said peptides in the mixture are conjugated to an immunogenic carrier and sorbed onto a pharmaceutically acceptable adjuvant.EFFECT: application of this group of inventions allows to obtain such peptide immunogens which carry minimally necessary antigenic determinants for formation of a specific immune response and contain antigenic regions of the GP protein of the Ebola virus that are immunogenic and that induce protective immunity against Ebola infection.5 cl, 4 tbl, 6 ex
Sulfo-containing polymers with its own antiviral activity // 2635558
FIELD: pharmacology.SUBSTANCE: invention relates to the high-molecular weight compounds of the medical purpose, more specifically to new synthetical sulfo-containing homo- and copolymers 2-acrylamido-2-methylpropansulfoacid with its own bioactivity that can be used in pharmacology in the capacity of the future-proof antiviral agents or can serve as the basis for the new effective and harmless antiviral medicinal agents and its pharmaceutical forms. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid of the stated below formula are obtained by the radical heterophase (co)polymerization in the ethanol at 70°C within 24 hours. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid have the molecular weight MM=(40-70)⋅103. where , m=100 mol. %, n=0; , m=(22.8-58.1) mol. %, n=(77.2-41.9) mol. %.EFFECT: invention allows to get nontoxical homo- and copolymer 2-acrylamido-2-methylpropansulfoacid with its own antiviral activity against the influenza viruses H3N2, H1N1.1 tbl, 2 ex
Pyrimidyl-di(diazadispiroalkane)s with antiviral activity // 2633699
FIELD: pharmacology.SUBSTANCE: compounds have a broad spectrum of antiviral activity and can be used for treatment and/or prevention of diseases caused by papillomavirus infection, infection caused by the immunodeficiency virus, cytomegalovirus or hepatitis B or C virus. In general formula I , X = CH2, Y = CH2CH2 or X = CH2CH2, Y = CH2; A is pyrimidine-4,6-diyl or pyrimidine-2,4-diyl, which may contain, as substituents, H, NO2, CHO, OH, OAlk, a halogen atom, NH(Alk), N(Alk) 2 group; wherein Alk is a linear or branched substituent having from 1 to 4 carbon atoms; Hal is a halogen atom, or X = Y = CH2; A is pyrimidin-4,6-diyl or pyrimidine-2,4-diyl, which has Cl, Br, CH3, HE atom as its substituent;Hal is a halogen, chlorine or bromine atom. Preference is given to compounds of formula (I) where X = CH2CH2, Y = CH2 or X = CH2, Y = CH2CH2, A = pyrimidine-4,6-diyl, which may have H, NO2, Alk group, as substituents; Hal = chlorine or bromine and Alk = methyl.EFFECT: increased composition application effeciency.11 cl, 2 dwg, 2 tbl, 13 ex
Antiviral drug as capsules and method for its preparation // 2633085
FIELD: pharmacology.SUBSTANCE: antiviral drug is made as a hard gelatin capsule containing granules comprising oseltamivir phosphate as an active ingredient and auxiliary additives: microcrystalline cellulose or lactose, povidone, aerosil, crospovidone or croscarmellose, sodium stearyl fumarate at a certain ratio of components. The method for antiviral drug production is implemented by wet granulation.EFFECT: invention allows preparation of an antiviral drug based on oseltamivir that quickly and completely releases the active substance, and is stable during storage.4 cl, 1 tbl
edicinal for vaginal application, with antiviral, antimicrobial, antifungal, antiprotozoal, antiinfectious, immunomodulating and antiinflammatory action, as ointment, gel, suppository // 2633056
FIELD: pharmacology.SUBSTANCE: medicament is presented comprising active substances, excipients and a consistently-forming base, characterized by comprising fluconazole, metronidazole, alpha- or beta- or gamma-recombinant interferon as active substances, disodium edetate and boric acid as adjuvants, and substances selected from the group: macrogol 400, macrogol 1500, macrogol 4000, vitepsol, glycerin, cocoa butter, paraffin, lanolin, vaseline, acetylphthalyl, GL type solid fat as a consistently forming base, wherein the drug components are in a specific ratio in g per 1 g of the agent.EFFECT: high therapeutic effect ensures rapid substances entry into the blood.1 cl

Dyetered diaminopyrimidine compounds and pharmaceutical compositions containing such connections // 2632907
FIELD: pharmacology.SUBSTANCE: invention relates to novel deuterated diaminopyrimidines of the general formula (I) and their pharmaceutically acceptable salts. In the general formula (I) R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R6, R7, R9, R10, R11, R12, R13a, R13b, R13c, R14a, R14b, R14c, R15a, R15b, R15c, R16, R17a, R17b, R18a, R18b, R19a, R19b, R20a and R20b independently hydrogen or deuterium; R5 is hydrogen, deuterium or halogen, R8 Represents a halogen; Provided that at least four of R1a, R1b, R1c, R2a, R2b, R2c, R3, R12, R13a, R13b, R13c, R14a, R14b, R14c, R19a, R19b, R20a or R20b are deuterium. The invention also relates to a process for the preparation of compounds of general formula (I) by reacting compound A6 with compound XV and to intermediates A6 and XV. In this case, in compound A6 R10, R11, R12, R13a, R13b, R13c, R14a, R14b, R14c, R15a, R15b, R15c, R16, R17a, R17b, R18a, R18b, R19a, R19b, R20a or R20b are independently selected from deuterium or hydrogen and at least one of them is deuterium; In compound XV R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R6, R7, R9 are independently selected from hydrogen or deuterium and at least one of them is deuterium; and R5 is hydrogen, deuterium or halogen; and R8 represents a halogen; X2 is selected from F, Cl, Br, I.EFFECT: compounds have ALK protein kinase inhibitory properties and can be used to treat or prevent cancer, impair cell proliferation, cardiovascular diseases, inflammation, infection, autoimmune diseases, organ transplantation, viral diseases, cardiovascular diseases or metabolic diseases.18 cl, 4 dwg, 1 tbl

Cyclosporin analogs molecules modified by 1 and 3 amino acids // 2630690
FIELD: pharmacology.SUBSTANCE: invention relates to cyclosporin-A analogs containing modifications of substituents at amino acids positions 1 and 3, according to the following Formula (I) .EFFECT: compounds have an affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressive activity compared to cyclosporin-A and its analogs modified only by position 1.22 cl, 1 dwg, 5 tbl, 26 ex

Drug with immunomodulatory effect // 2629331
FIELD: pharmacology.SUBSTANCE: drug with an immunomodulatory and antiviral effect, which is an extract of the herbaceous saltwort [Salsola laricifolia], obtained by extraction of dry herbaceous saltwort [Salsola laricifolia] with 30-80% aqueous solution of polyhydric alcohol at 60-90°C; using the extractant:dry grass ratio of 1:(0.003-0.6), respectively.EFFECT: drug has a pronounced immunomodulatory and antiviral effect, effectively increases the nonspecific resistance of the mammalian organism.10 cl, 9 dwg, 67 tbl, 55 ex

Recombinant l1hpv16 gene, recombinant pqe-l1/16 plasmid, l1hpv16 protein and their application // 2628693
FIELD: biotechnology.SUBSTANCE: recombinant gene encoding a human papillomavirus 16 type L1 protein is provided, with codons optimised for heterologous expression in E. coli strains. An expression plasmid vector pQE-L1/16 carrying this recombinant gene is presented. A method for recombinant L1HPV16 protein production using this vector, which is used to transform E. coli strains is provided. An immunogenic composition and vaccine are provided for induction of specific cellular and humoral immunity against HPV16 containing recombinant L1HPV16 protein.EFFECT: group of inventions allows to obtain a stable purified immunogenic L1HPV16 protein, allows to reduce the cost of its preparation process for use in effective immunogenic compositions and vaccines against type 16 human papillomavirus.6 cl, 3 dwg, 1 tbl, 5 ex
External application means for chronic dermatosis treatment, and method for its production // 2628535
FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex

utant polymerases of hepatitis b virus // 2625021
FIELD: biotechnology.SUBSTANCE: invention relates to biochemistry, in particular, to mutant HBV polymerase polypeptide containing a mutant HBV polymerase domain with the internal deletion that suppresses the polymerase functional activity, and mutant RNase H domain with the internal deletion and mutations that suppresses the functional activity of RNase H. This invention also relates to a hybrid protein containing the said mutant HBV polymerase polypeptide and core HBV polypeptide or immunogenic HBsAg envl and env2 domains. The said mutant polypeptide and hybrid proteins are used for induction or stimulation of the immune response against HBV. The present invention also discovers a nucleic acid molecule, an expression vector and a composition and kit for the treatment or prevention of the infection caused by HBV or HBV-associated diseases and of pathological conditions. The present invention also discloses the host-cell, a method of obtaining the hybrid proteins and a method of obtaining viral particles which uses the said expression vector.EFFECT: invention provides for improving the immunizing capacity of mutant HBV polypeptides preserving security when using them.46 cl, 11 dwg, 2 ex
ethod of obtaining transfer factor for preventing viral bird diseases // 2624504
FIELD: veterinary medicine.SUBSTANCE: method of producing a transfer factor for the prevention of viral bid diseases, comprising preparing lymphocytes extract, hydrolysis by DNA, dialysis with subsequent preservation or lyophilization the title product, wherein the spleen of vaccinated against one or more infections, or recovered chickens or chickens is taken as a lymphocyte source.EFFECT: efficient preparation of the transfer factor from an extract of lymphocytes with increased yield.2 tbl, 2 ex
Way to prevent viral diseases of birds // 2624503
FIELD: veterinary medicine.SUBSTANCE: way includes the injection of transfer-factor to the bird. Transfer factor is obtained from blood leukocytes vaccinated against one or more infections or outgrown their chickens or chickens. The drug is injected to the poultry of all ages aerosol melkodispersno one dose on the head upon exposure of 20-25 minutes. Aerosol producing distilled water with the addition of 10% glycerol to the volume.EFFECT: use of the claimed invention is highly effective for the prevention of infectious disease in birds and improve preventive vaccines.4 cl, 2 tbl, 3 ex
eans for skin diseases treatment have anti-inflammatory, wound-healing, antibacterial, anti-viral, anti-fungal action // 2623061
FIELD: pharmacology.SUBSTANCE: invention relates to a skin treatment agent having an anti-inflammatory, anti-bacterial, anti-viral, anti-fungal activity that is an oil extract of Gynura procumbens leaves obtained in a specific manner.EFFECT: agent is effective for skin diseases treatment.6 cl, 16 ex
ethod for calves respiratory diseases prevention // 2620548
FIELD: veterinary medicine.SUBSTANCE: clinically healthy calves 20-30 days of age are given xymedon hydrochloride mixed with a 3.5% alcohol tincture of scotch pine (Gemmue Pini) buds, herbs and inflorescences of Ehinacea purpurea L., rhizomes and roots of elecampane (Inula Neleium L.), taken in the ratio 2:1:1, calculated based on 2.0 g of xymedon hydrochloride to 100.0 ml of 3.5% alcohol tincture of scotch pine (Gemmue Pini) buds, herbs and inflorescences of Ehinacea purpurea L., rhizomes and roots of elecampane (Inula Neleium L.), dosed as 1.5-2.0 ml/kg of body weight for the first time 18-24 hours before and twice after immunization. The immunization is carried out three times by subcutaneous injection of hyperimmune serum containing antihaemagglutinin to viruses PG-3 in titer of 1:1280, IRT - in titer of 1:256 and VD-BS - in titer of 1:1024, adenovirus - in titer of 1:256, PC-virus - in titer of 1:128, dosed as 1.0 ml/kg body of weight at an interval of 10-12 days.EFFECT: higher preventive effect.4 tbl, 3 ex
ethod for dynamic control of efficiency of treatment of cervical intraepithelial lesions of cervix uteri by means of diindolylmethane-based suppositories // 2618427
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynaecology, and can be used for dynamic control of treatment of cervical intraepithelial lesions of cervix uteri. For this purpose after application of medication based on active substance 3,3'-diindolylmethane in dosage form "vaginal suppositories" in dose 200 mg/day for 6 months efficiency of therapy with application of colposcopic methods is assessed after 6 and 12 months of therapy.EFFECT: method makes it possible to reliably assess therapy efficiency and speed of onset of therapeutic effect.4 tbl, 5 ex

Pharmaceutical composition of dioxotetrahydroxytetrahydronaphthalene // 2618417
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition is made in the form of nasal cream containing an active substance of dioxotetrahydroxytetrahydronaphthalene and exicipients such as citric acid monohydrate, poloxamer 338, macrogol 20 cetostearyl ether, cetostearyl alcohol, solid paraffin, liquid paraffin, dimethicone 100 and propylene glycol.EFFECT: stability when stored at temperatures above 25 degrees.2 cl, 15 dwg, 7 tbl

Adamantylamides of sulfur-containing acids and their anti-influenza activity // 2617850
FIELD: pharmacology.SUBSTANCE: invention relates to new synthetic compounds, namely 1-(1-adamantyl)ethylamide-3-(2-thienyl)-propenoic acid (TEPr-Rem) 1-adamantylamide-3-(2-thienyl)-propenoic acid (TEPr-Amt) and 1-(1-adamantyl)ethylamide-4-(2-thienyl)-butyric acid (TEBu-Rem) The proposed compounds: TEPr-Rem, TEPr-Amt and TEBu-Rem inhibit reproduction of pathogenic influenza virus A/H1N1pdm2009 and A/H5N1 strains, also provide virucidal effect against virus A/H5N1 influenza particles.EFFECT: increased activity of compounds.3 cl, 6 ex, 8 dwg
ethod for measles, mumps, rubella vaccination for hiv-infected children // 2616234
FIELD: medicine.SUBSTANCE: for specific prevention of measles, mumps, rubella for HIV-infected children, clinical, immunological and serological studies in HIV-infected children are conducted. Then, the primary immunization with live vaccines is carried out twice with an interval of 6 months. After 4 years, revaccination is performed, then every 4-5 years dynamic control of specific immunity to measles virus, mumps, rubella is performed. In the absence of protective antibod titres, re-introduction of vaccines/vaccine is performed.EFFECT: application of the proposed method will increase the efficiency of vaccination with live vaccines against measles, mumps, rubella, and significantly reduce the percentage of seronegative HIV-infected children.3 ex, 1 tbl
Pharmaceutical enteric coated compositions based on mycophenolic acid salt // 2615397
FIELD: pharmacology.SUBSTANCE: group of inventions discloses a pharmaceutical composition comprising of a mycophenolate salt covered with an enteric coating which provides the release of mycophenolate in the upper part of the intestinal tract, and a method of immunosuppression in a patient involving the administration of a therapeutically effective amount of said composition to a patient in need of such therapy.EFFECT: increased efficiency of the composition.15 cl, 2 ex, 1 tbl
Antiviral agents based on culture extract of "hairy roots" of nitraria schoberi l. // 2615376
FIELD: pharmacology.SUBSTANCE: invention relates to the antiviral agent based on the culture extract of "hairy roots" of Nitraria schoberi L., that is a dry plant extract. The dry plant extract contains dry extractives not less than 42.7%, the total protein not less than 28±6 mg/g, polysaccharides in the amount of not less than 205±17 mg/g, phenolic compounds in the amount of, at least, 9±1 mg/g, flavonoids in the amount of not more than 5 mg/g.EFFECT: expanding the raw material base for preparing antiviral agents and an assortment of antiviral agents relative to influenza A virus of subtypes H3N2 and H5N1.2 cl, 4 dwg, 5 tbl, 5 ex
ethod of prevention of colibacillosis in calves // 2612081
FIELD: agriculture.SUBSTANCE: invention relates to the field of veterinary medicine and is intended for prevention of colibacillosis in calves. The immunization of down-calving cows is performed 1.5-2 months before the delivery with the vaccine against colibacillosis of animals Coli-Vack K88, K99, 987P, F41, TL- and TC-anatoxins twice with an interval of 15 days, the first dose is 10 cm3, the second is 15 cm3. The visceral novocaine blockade on L.G. Smirnov is performed to calves received from these cows within 1-2 hours after birth and on the 7th day of life.EFFECT: method increases the level of specific and non-specific humoral and cellular immunity of calves; reduces the incidence of colibacillosis.3 tbl, 1 ex

Vaccine compositions against human papilloma virus (hpv), containing aluminium adjuvant, and methods of production thereof // 2610174
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for producing human papilloma virus vaccine. Vaccine composition against human papilloma virus includes: a) therapeutically effective amount of virus-like particles (VLP) HPV, adsorbed on aluminium adjuvant; b) mannitol and saccharose, c) optionally salt. Wherein composition contains: 1) virus-like particles HPV of at least one type, adsorbed on aluminium adjuvant, present in concentration equal to 10-200 mcg/ml, wherein virus-like particles are selected from group, consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73 and HPV82; and 2) from approximately 1 % to approximately 10 wt/vol. of mannitol; and 3) from approximately 0.5 % to approximately 10 % of sucrose. Composition is frozen or lyophilized and composition is stable at storage during 1 month at 25 °C after stress caused by process of lyophilization or freezing-thawing. Group of inventions also relates to methods of producing said vaccine.EFFECT: use of given inventions enables to obtain solid preparation of vaccine HPV (frozen or lyophilized) containing combination of excipients mannitol and saccharose, providing preservation of antigenicity of lyophilized vaccine preparation.21 cl, 9 ex, 3 tbl, 15 dwg
ethod of production of rabies diagnostic serum // 2609766
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to immunology, and can be used for production of rabies diagnostic serum. For that immunization of animals-producers with antigen material and adjuvant is made. As adjuvant mixture of lanolin and polyethylsiloxane liquid is used, taken in weight ratio 1:2–9, respectively, immunomodulator immunofan in amount of 0.8–1.2 ml per one animal is additionally used. Immunization is performed 5 times, wherein at first three times every 20–24 hours antigen is introduced together with adjuvant, taken in weight ratio 1:0.8–1.0 in amount of 10–14 ml of mixture of antigen with adjuvant per one animal and simultaneously – immunofan. Then 12–16 days later antigen is introduced in amount of 5–7 ml of antigen per one animal and simultaneous immunofan, then 7–8 days later antigen is introduced in amount of 5–7 ml of antigen per one animal. Besides, method of producing rabies diagnostic serum uses polyethyl siloxane liquid PES-2 or PES-3 as polyethylsiloxane liquid, and antigen material is "sheep" strain of rabies virus VGNKI and reference strain CVS.EFFECT: application of given method allows to increase target product quality due to increased specific activity of serum.4 cl, 5 ex

Fcγriib-specific fc-antibody // 2608504
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a polypeptide, comprising a Fc-domain of an antibody with at least one amino acid modification, which has high activity of binding with FcγRIIb in comparison with initial polypeptide, where value [value KD polypeptide containing Fc-domain of antibody against FcγRIIa (type R)]/[value KD polypeptide containing Fc-domain of antibody against FcγRIIb] is equal to or greater than 1.2, where value [value KD for higher activity of binding polypeptide containing Fc-domain of antibody against FcγRIIa (type R) and FcγRIIa (type H)]/[value KD for higher activity of binding initial polypeptide on FcγRIIa (type R) and FcγRIIa (type H)] is 0.7 or more, and where amino acid modification is a replacement of Pro in position 238 (EU numeration) with Asp or replacement of Leu in position 328 (EU numeration) with Glu. Described are methods of producing said polypeptide and use thereof.EFFECT: invention widens range of therapeutic and preventive agents.20 cl, 16 dwg, 12 tbl, 9 ex

Strain of lactic acid bacteria, drug, food product, beverage, as well as fodder containing strain of lactic acid bacteria // 2607370
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Strain Lactobacillus paracasei MCC1849 with high stimulating production of IL-12 activity.EFFECT: strain is used as ingredient of medicinal agent for immune stimulation, agent against influenza virus, food product, beverage, fodder and agent stimulating production of IL-12.8 cl, 2 dwg, 3 tbl, 3 ex
Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs // 2606845
FIELD: pharmaceutics.SUBSTANCE: group of inventions refers to medicine and pharmacology, and can be used for preparing solid pharmaceutical composition, wherein the solid pharmaceutical composition contains: (i) amorphous solid solution of 9-[2-[bis[(pivaloiloxy)-methoxy]phosphinyl]methoxy]ethyl]adenine (AD) and a copolymer of vinylpyrrolidone and vinyl acetate and (ii) one or more pharmaceutically acceptable inactive ingredients selected from microcrystalline cellulose, silicon dioxide and magnesium stearate, wherein the solid pharmaceutical composition is stable, such that when the solid pharmaceutical composition is stored at 40 °C and relative humidity of 75 % in a closed container for 3 months, amount of impurities presented in the solid pharmaceutical composition, is not more than 0.74 weight. % in relation to the initial number of AD, wherein the admixture is 9-[2-(pivaloiloxy)-methoxyphosphinyl]methoxy]ethyl]adenine; at that, the method comprises the following steps: (i) producing amorphous solid solution of AD and copolymer of vinylpyrrolidone and vinyl acetate by dissolving the initial quantity of AD and copolymer of vinylpyrrolidone and vinyl acetate in a volatile organic solvent selected from ketones and halocarbons, evaporation of the volatile organic solvent and (ii) dry mixing of the obtained amorphous solid solution with one or more pharmaceutically acceptable inactive ingredients. Solid pharmaceutical composition and packing system are also disclosed.EFFECT: group of inventions ensures production of highly-stable composition having storage stability.10 cl, 5 tbl, 3 ex
Sulphonic acid salts of heterocyclylamide-substituted imidazoles // 2606639
FIELD: chemistry.SUBSTANCE: invention relates to a salt of a compound of formula wherein R1 denotes methyl, ethyl, butyl or cyclopropylmethyl, R2 denotes phenyl, where phenyl contains a substitute selected from a group, including trifluoromethoxy group and difluoromethoxy group, and R3 denotes hydrogen, methyl, chloro, methoxy group or trifluoromethyl, with organic sulphonic acid or its solvate, or hydrate, their solvates and hydrates and their use as antiviral agents.EFFECT: novel compounds.14 cl, 1 dwg, 4 tbl, 1 ex

ethod of treating dengue fever // 2605904
FIELD: chemistry.SUBSTANCE: invention relates to compounds used in pharmaceutical compositions for treating diseases caused by dengue virus, having formulae: , where: R1 is aryl, where said aryl is phenyl or naphthyl, optionally substituted with one or three substitutes independently selected from a group consisting of following: C1-6alkoxy; R1a is C1-6alkyl; R1b is -OR1a or -N(R1a)2; R2a and R2b (i) are independently selected from a group consisting of following: hydrogen, C1-10alkyl, -(CH2)mC(=O)R1b and aryl-C1-3alkyl; R3 is C1-10alkyl or aryl-C1-3alkyl, where said aryl is phenyl; R4 is hydrogen; R6 is A, B, C or D, where R8 is hydrogen or C1-3alkyl; R5 and7 are independently selected from hydrogen, C(=O)C1-6alkyl; m ranges from 0 to 3; or its pharmaceutically acceptable salt.EFFECT: treating diseases caused by dengue virus.19 cl, 2 tbl, 2 ex

Derivatives of 2-(adamant-2-yl)ethylamine, having potential antiviral activity // 2605698
FIELD: chemistry.SUBSTANCE: invention relates to novel adamantane-containing amines of general formula, more specifically to 2-(adamant-2-yl)pentane-1-amine and 2-(adamant-2-yl)phenylethyl-1-amine, in general formula R=C3H7, C6H5.EFFECT: novel compounds exhibit antiviral activity.1 cl, 1 tbl, 2 ex

Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars // 2603769
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a compound and its pharmaceutically or cosmetically acceptable salts, used as an inhibitor of sodium-dependent glucose co-transporter, antioxidant and for depigmenting the skin in medicine and cosmetology, of the following formula (I): , as well as methods of its production and compositions based thereon, where n, m and p are independently 0 or 1, R denotes CH2OH or CH2OR11,R1 and R2 are OH or OR15, R3 is OH or OR18, R4 is a hydrogen atom, when n=1, or a hydrogen atom, a halogen atom or OH group, when n=0; X1 is a hydrogen atom, halogen atom, OH group, (C1-C6)-alkyl or OR24; U, V and W denote phenyl, pyrazolyl, N-(C1-C6)alkyl-pyrazolyl or thienyl optionally substituted by one or more substitutes selected from a halogen atom, OH, (C1-C6)-alkyl and OR24; R11, R15 and R18 are aryl-(C1-C6)-alkyl and R24 is (C1-C6)-alkyl or aryl-(C1-C6)-alkyl. In the proposed methods a compound of formula (II) is fluoridated, or compounds of formulae (VIII) and (XI) , are bound, wherein OH group in position of R4 in the binding product of formula (I) is optionally substituted by halogen, or the compound of formula (I) is bromated with subsequent reconstruction, or a compound of formula (XVI) is associated with a compound of formula (V), where R, R1, R2, R3, X1, U, V, W, n, m and p are given above, A1 is -Li or -Mg-Hal, Hal is a halogen atom, R9 is a leaving group.EFFECT: new agent is disclosed which is suitable for bleaching and depigmentation of skin, as an antioxidant, for inhibition of sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, and diseases, where such inhibition is effective, in particular in the treatment or prevention of diabetes and diabetes-related complications.21 cl, 69 ex, 11 dwg

Veterinary composition and method for improving viability of animals, stimulation of body weight gain in mammals and birds, increasing efficiency of immunising, preventing and/or treating infectious diseases (versions) // 2603623
FIELD: veterinary science.SUBSTANCE: present group of inventions relates to veterinary science and concerns improving viability and stimulation of body weight gain of agricultural animals, mammals and birds. Method comprises administering a composition containing activated potentiated antibodies to insulin receptor, or insulin receptor and gamma-interferon, or insulin receptor, gamma interferon and CD4 receptor, or insulin receptor and CD4 receptor.EFFECT: introduction of said compositions provides higher productivity of farm animals with no side effects.14 cl, 17 tbl, 2 dwg, 7 ex

Inactivated sorptive vaccine to fmd types a, o, asia-1 // 2603003
FIELD: veterinary science; biotechnology.SUBSTANCE: invention relates to veterinary virology and biotechnology. Vaccine contains active substance and target additives. As active substance, vaccine contains mixture of avirulent purified antigen material of foot FMD A strains No. 2171/Kabardino-Balkar/2013, A No. 2187/Kuti/2013, Asia-1 No. 1946/Shamir 3/89 and O No. 2123/South Ossetia/2011, obtained from transplantable cell culture VNK-21, representing suspension, containing mainly 146S and 75S immunogenic components of FMD, adjuvants: aluminium hydroxide with saponin and preserving medium in effective ratios.EFFECT: vaccine exhibits high immunogenicity and is capable of providing effective protection against homologous infectious agents, circulating in Transcaucasus, Central Asia, middle and Near East.16 cl, 4 dwg, 7 tbl, 5 ex

ethod of treating focal form of mixed encephalitis-borreliosis infection in acute period // 2602740
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to neurology, and can be used for treating patients with focal form of mixed encephalitis-borreliosis infection in acute period. For this purpose at background of etiotropic and pathogenetic therapy intravenous introduction of normal human immunoglobulin is made in daily dose of 2.5 g in course of 3-5 days, inclusive, regardless of day of disease.EFFECT: method allows reducing risk of residual neurological deficiency due to formation of own active specific immunity at low probability of protein overload.1 cl, 2 tbl, 2 ex

ethod of treating patients with facial pain with postherpetic ganglionitis of a head // 2601408
FIELD: medicine.SUBSTANCE: invention refers to medicine and is aimed at treating patients with facial pain with postherpetic ganglionitis of a head. Content of specific G antibodies to the herpes simplex virus (HSV) type 1 and cytomegalovirus, content of alpha and gamma interferons, serum and spontaneous interferon in blood, in the oral fluid: concentration of A secretory immunoglobulin, alpha interferon and lactoferrin level. Index of microorganisms adsorption reaction is calculated (MAR). If the values of serum and spontaneous interferon do not exceed 2 units/ml, content of specific G antibodies to HSV type 1 is from 1:2973.75 and higher, to cytomegalovirus - from 1:2916.91 and higher, of alpha interferon - from 194.78 unit/ml and lower, of gamma interferon - from 16.87 unit/ml and lower, and in the oral fluid: concentration of secretory immunoglobulin - from 225.11 mg/ml and lower, concentration of alpha interferon - from 8.6 pg/ml and lower, lactoferrin level - from 9613.3 ng/ml and lower, MAR index - from 6.5 and higher, the acyclic nucleosides group drug is prescribed in complex, anti-inflammatory agents, anti-histamine drugs, immunomodulators.EFFECT: using the invention provides increase in treatment efficacy due to comprehensive application of drug therapy preparations.1 cl, 1 ex

Uracil or thymine derivatives for treating hepatitis c // 2599635
FIELD: chemistry.SUBSTANCE: invention relates to a compound of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalene-2-yl)methanesulfonamide or its pharmaceutically acceptable salt for use as a medicinal agent for inhibiting replication of hepatitis C virus (HCV), as well as to a medicinal agent containing a therapeutically effective amount of the said compound or its pharmaceutically acceptable salt.EFFECT: technical result is stable indices of efficiency of treating, relieving symptoms of hepatitis C, providing partial or complete reduction of symptoms.5 cl, 46 dwg, 40 tbl, 140 ex

Improved vaccination against influenza // 2599496
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used for inducing cross-protection against at least one heterosubtypic strain of influenza. To induce cross-protection against at least one heterosubtypic strain of influenza in comparison with influenza strains, antigens of which are present in influenza vaccine, influenza vaccine containing and HA and NA is administered. Where vaccine is a virosomal influenza vaccine, which does not contain an auxiliary agent and which is administered intramuscularly at least three times in one year. Group of inventions also relates to a method of inducing cross-protection against influenza H5N1 strain and to a method for influenza vaccination.EFFECT: use of present group of inventions makes it possible to provide cross-protection due to administration of virosomal seasonal vaccines, which do not contain an auxiliary agent by normal intramuscular administration.13 cl, 7 ex, 9 dwg
ethod of treating acute hepatitis b or c with severe clinical course // 2599037
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns new therapeutic regimens of acute viral hepatitis treatment, making it possible to reduce duration of clinical manifestation and preventing transition in the chronic course of the disease. Method of treating acute hepatitis B or C with severe clinical course consists in intravenous drop introduction of preparation 2 times a week for three months, wherein first drop introduction is 4.0 ml of Laennek, dissolved in 250 ml of 0.9 % sodium chloride water solution or 5 % glucose solution, through ulnar vein for 1 hour 20 minutes, second and subsequent introductions consist 10.0 ml of Laennek, dissolved in 250 ml of 0.9 % saline solution through ulnar vein for 1.5 hours.EFFECT: method of treating acute hepatitis B or C is disclosed.1 cl, 2 ex
Chimeric immunoglobulin preparation with specific antiviral or antibacterial effect // 2599029
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to immunology, and can be used for producing of chimeric immunoglobulin preparation with specific antiviral or antibacterial effect. Chimeric immunoglobulin preparation contains immune proteins from milk and/or colostrum from immunized cows and stabilizing additives. Chimeric partially humanized bovine secretory immunoglobulin A (S-IgA) is used as immune protein, in which bovine secretory component is substituted by recombinant or donor human secretory component.EFFECT: using this composition allows to create high-purity immunoglobulin preparation based on S-IgA with reduced immunogenicity and reactogenicity suitable for oral, parenteral and local adminstration.3 cl, 5 ex

Antiviral compound of multiple action, its composition and method of treating viral diseases // 2597150
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine. Method for prevention and/or treatment of viral infections, involving administering the composition. Disclosed is a composition of high-purity extract yeast RNA having weight not less than 75 % of fragments 25±10 nucleotides, with purity preferably at least 99 %, in combination with mannitol in the ratio of 2:1 to 3:1, where the extract yeast RNA is preliminarily heated mannitol, the extract of yeast RNA is not less than 50 % of composition weight. Disclosed is a method of preparing said composition.EFFECT: presented group of inventions provides the new antiviral agent with prolonged action.28 cl, 15 dwg, 14 tbl, 2 ex

ethods and compositions for treating persistent infections // 2596491
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used composition for treating persistent infection, angioimmunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma. Composition contains a PD-1 activity or expression inhibitor. Group of inventions also relates to a composition containing an antigen-specific T-cell, brought into contact with a compound which reduces expression or activity of PD-1.EFFECT: using present group of inventions enables to block expression level of PD-1, which leads to increased CD8+ T-cell proliferation.21 cl, 8 dwg, 1 tbl, 14 ex
 
2551171.
Up!